Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT ALL/MRD2025 treatment protocol for adult acute lymphoblastic leukemia
jRCTs071250059Recruiting
- Sponsor
- Kyushu University Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of blinatumomab and prednisolone in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (3 arms), sponsored by Kyushu University Hospital. Primary endpoint: 3-year disease-free survival rate. Started Sep 2025; status: recruiting.
02
Drugs
blinatumomabprednisolone
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on jRCTs071250059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250059.